Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
New Insights into Cellular Transplantation and Immunotherapy
share announcement

New Insights into Cellular Transplantation and Immunotherapy

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".

Deadline for manuscript submissions: closed (15 June 2022) | Viewed by 11958

Special Issue Editor

Dr. Takafumi Yokota

E-Mail Website
Guest Editor
Department of Hematology and Oncology, Osaka University Graduate School of Medicine, C9, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
Interests: hematopoietic stem cells; stem cell biology; stem cell transplantation; aging; leukemia stem cells; hematopoietic neoplasms

Special Issue Information

Dear Colleagues,

Cellular transplantation has long been used in various medical fields to replace diseased or abnormal cells and to regenerate heathy organs. In addition to traditional transplantation, recent biotechnological advances have enabled us to engineer artificially designed cells from our own (e.g., chimeric antigen receptor T cells) and to use them in clinical practice, such as immunotherapy. The notion of such “designer cells” has been attracting broad attention in the cellular transplantation field because it paves the way for a prosperous future for customized medicine to cure not only cancers but also intractable genetic diseases.

This Special Issue invites manuscripts providing new insights into cellular transplantation and immunotherapy. We are interested in a wide range of work from different medical sections, including cardiovascular biology, gastroenterology, hepatology, endocrinology, immunology, hematology, and neuroscience. Review or original articles on stem cell biology, cell culture systems, and tissue engineering for transplantation are also important. Finally, comprehensive papers regarding ethics, safety, and technology relevant to the new era of cellular transplantation are also welcome. 

Dr. Takafumi Yokota
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transplantation
  • stem cells
  • designer cells
  • tissue engineering
  • cell therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2653 KiB  
Communication
Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
by Alexander D. Heini, Ulrike Bacher, Naomi Porret, Gertrud Wiedemann, Myriam Legros, Denise Stalder Zeerleder, Katja Seipel, Urban Novak, Michael Daskalakis and Thomas Pabst
Cells 2022, 11(17), 2747; https://doi.org/10.3390/cells11172747 - 2 Sep 2022
Cited by 7 | Viewed by 4167
Abstract
Mantle cell lymphoma (MCL) is a rare type of B-cell Non-Hodgkin lymphoma (NHL) affecting predominantly male patients. While complete remissions following first-line treatment are frequent, most patients ultimately relapse, with a usually aggressive further disease course. The use of cytarabine-comprising induction chemotherapy and [...] Read more.
Mantle cell lymphoma (MCL) is a rare type of B-cell Non-Hodgkin lymphoma (NHL) affecting predominantly male patients. While complete remissions following first-line treatment are frequent, most patients ultimately relapse, with a usually aggressive further disease course. The use of cytarabine-comprising induction chemotherapy and autologous stem cell transplantation, Rituximab maintenance, Bruton’s tyrosine kinase (BTK) inhibitors and CAR T therapy has substantially improved survival. Still, options for patients relapsing after CAR T therapy are limited and recommendations for the treatment of these patients are lacking. We report two cases of patients with mantle cell lymphoma who relapsed after CAR T therapy and were treated with the bispecific CD20/CD3 T cell engaging antibody glofitamab. Both patients showed marked increases of circulating CAR T cells and objective responses after glofitamab administration. Therapy was tolerated without relevant side effects in both patients. One patient completed all 12 planned cycles of glofitamab therapy and was alive and without clinical progression at the last follow-up. The second patient declined further treatment after the first cycle and succumbed to disease progression. We review the literature and investigate possible mechanisms involved in the observed responses after administration of glofitamab, such as proliferation of CAR T cells, anti-tumor effects of the bispecific antibody and the role of other possibly contributing factors. Therapy with bispecific antibodies might offer an effective and well-tolerated option for patients with mantle cell lymphoma relapsing after CAR T therapy. Full article
(This article belongs to the Special Issue New Insights into Cellular Transplantation and Immunotherapy)
►▼ Show Figures

Figure 1

14 pages, 17873 KiB  
Article
Pluripotent Stem Cell-Derived Hepatocytes Inhibit T Cell Proliferation In Vitro through Tryptophan Starvation
by Marco Romano, Raul Elgueta, Daniel McCluskey, Ana Maria Ortega-Prieto, Emilie Stolarczyk, Francesco Dazzi, Baltasar Lucendo-Villarin, Jose Meseguer-Ripolles, James Williams, Giorgia Fanelli, David C. Hay, Fiona M. Watt and Giovanna Lombardi
Cells 2022, 11(1), 24; https://doi.org/10.3390/cells11010024 - 22 Dec 2021
Cited by 7 | Viewed by 5025
Abstract
Regenerative medicine aims to replace damaged tissues by stimulating endogenous tissue repair or by transplanting autologous or allogeneic cells. Due to their capacity to produce unlimited numbers of cells of a given cell type, pluripotent stem cells, whether of embryonic origin or induced [...] Read more.
Regenerative medicine aims to replace damaged tissues by stimulating endogenous tissue repair or by transplanting autologous or allogeneic cells. Due to their capacity to produce unlimited numbers of cells of a given cell type, pluripotent stem cells, whether of embryonic origin or induced via the reprogramming of somatic cells, are of considerable therapeutic interest in the regenerative medicine field. However, regardless of the cell type, host immune responses present a barrier to success. The aim of this study was to investigate in vitro the immunological properties of human pluripotent stem cell (PSC)-derived hepatocyte-like cells (HLCs). These cells expressed MHC class I molecules while they lacked MHC class II and co-stimulatory molecules, such as CD80 and CD86. Following stimulation with IFN-γ, HLCs upregulated CD40, PD-L1 and MHC class I molecules. When co-cultured with allogeneic T cells, HLCs did not induce T cell proliferation; furthermore, when T cells were stimulated via αCD3/CD28 beads, HLCs inhibited their proliferation via IDO1 and tryptophan deprivation. These results demonstrate that PSC-derived HLCs possess immunoregulatory functions, at least in vitro. Full article
(This article belongs to the Special Issue New Insights into Cellular Transplantation and Immunotherapy)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 289 KiB  
Review
The Impact of Infused Autograft Absolute Numbers of Immune Effector Cells on Survival Post-Autologous Stem Cell Transplantation
by Luis F. Porrata
Cells 2022, 11(14), 2197; https://doi.org/10.3390/cells11142197 - 14 Jul 2022
Cited by 7 | Viewed by 2154
Abstract
Autologous stem cell transplantation treatment has been viewed as a therapeutic modality to enable the infusion of higher doses of chemotherapy to eradicate tumor cells. Nevertheless, recent reports have shown that, in addition to stem cells, infusion of autograft immune effector cells produces [...] Read more.
Autologous stem cell transplantation treatment has been viewed as a therapeutic modality to enable the infusion of higher doses of chemotherapy to eradicate tumor cells. Nevertheless, recent reports have shown that, in addition to stem cells, infusion of autograft immune effector cells produces an autologous graft-versus-tumor effect, similar to the graft-versus-tumor effect observed in allogeneic-stem cell transplantation, but without the clinical complications of graft-versus-host disease. In this review, I assess the impact on clinical outcomes following infusions of autograft-antigen presenting cells, autograft innate and adaptive immune effector cells, and autograft immunosuppressive cells during autologous stem cell transplantation. This article is intended to provide a platform to change the current paradigmatic view of autologous stem cell transplantation, from a high-dose chemotherapy-based treatment to an adoptive immunotherapeutic intervention. Full article
(This article belongs to the Special Issue New Insights into Cellular Transplantation and Immunotherapy)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop